Opus Genetics, Inc.

IRD • Biotechnology

$4.00

▼ -0.01 (-0.25%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$444.51M

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 6.43Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:56 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$4.00

Change-0.25%

Shares Out111.38M

Market Cap$444.51M

Enterprise Value$390.63M

52W Range1.10 - 5.81

Beta0.58

P/E-4.13

P/S45.10

P/B-34.23

P/FCF-8.33

EV/Sales39.63

Price$4.00

Change-0.25%

Shares Out111.38M

Market Cap$444.51M

Enterprise Value$390.63M

52W Range1.10 - 5.81

Beta0.58

P/E-4.13

P/S45.10

P/B-34.23

P/FCF-8.33

EV/Sales39.63

EV/EBITDA-7.18

EV/FCF-7.32

Earnings Yield-24.21%

FCF Yield-12.01%

Dividend Yield0.00%

Gross Margin100.00%

Oper. Margin-2.72%

Profit Margin-3.49%

Debt/Eq0.00

Current Ratio6.43

Quick Ratio6.43

Target$12.60

Target Upside215.00%

Target Median$10.00

Target Range8.00 - 20.00

Volume513.21K

Avg Volume941.45K

EPS Surprise-0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

20/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 6.43Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

IRD

Analyst sentiment

Based on 9 analyst votes · 2026-10-20

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$8.00

Promedio

$9.00

Mediana

$9.00

Alto

$10.00

Resumen de la compañía

IPO: 1/19/2015

Industria: Biotechnology

P/B i: -34.23

Deuda / Patrimonio i: 0.00

Margen operativo: -271.90%

Margen neto: -349.33%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 6.43

Ratio rápido: 6.43

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 1 venta interna de alto volumen detectada

Gagnon Robert E.

Transacción: 07/23/2026

VENTA

Cambio

-7,783

Precio

$2.95

Presentación

07/27/2026

Tipo

VENTA

Magrath George

Transacción: 07/23/2026

VENTA

Cambio

-9,475

Precio

$2.95

Presentación

07/27/2026

Tipo

VENTA

SCHACHLE JOSEPH K

Transacción: 07/23/2026

VENTA

Cambio

-4,644

Precio

$2.94

Presentación

07/27/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Gagnon Robert E.	VENTA	-7,783	$2.95	07/23/2026	07/27/2026
Magrath George	VENTA	-9,475	$2.95	07/23/2026	07/27/2026
SCHACHLE JOSEPH K	VENTA	-4,644	$2.94	07/23/2026	07/27/2026
YERXA BENJAMIN R	VENTA	-7,429	$2.97	07/23/2026	07/27/2026
Foundation Fighting Blindness Retinal Degeneration Fund	VENTA	-1,700,000	$4.35	05/18/2026	05/20/2026
Gagnon Robert E.	VENTA	-7,842	$5.18	04/23/2026	04/27/2026
Jayagopal Ashwath	VENTA	-7,542	$5.19	04/23/2026	04/27/2026
Magrath George	VENTA	-9,511	$5.22	04/23/2026	04/27/2026
Zaremba Rabourn Amy	VENTA	-1,641	$5.20	04/23/2026	04/27/2026
SCHACHLE JOSEPH K	VENTA	-4,697	$5.22	04/23/2026	04/27/2026
YERXA BENJAMIN R	VENTA	-7,470	$5.24	04/23/2026	04/27/2026
Ainsworth Sean	COMPRA	+24,367	Not reported	04/20/2026	04/22/2026
Bennett Jean	COMPRA	+24,367	Not reported	04/20/2026	04/22/2026
Benton Susan	COMPRA	+24,367	Not reported	04/20/2026	04/22/2026
Gallagher Cam	COMPRA	+24,367	Not reported	04/20/2026	04/22/2026
Graves Adrienne L	COMPRA	+24,367	Not reported	04/20/2026	04/22/2026
MANUSO JAMES S J	COMPRA	+24,367	Not reported	04/20/2026	04/22/2026
Rodgers Richard J	COMPRA	+24,367	Not reported	04/20/2026	04/22/2026
Jayagopal Ashwath	VENTA	-3,719	$5.12	03/16/2026	03/18/2026
Magrath George	VENTA	-24,438	$5.21	03/16/2026	03/18/2026

Sobre la compañía

Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Fuente - Link

Competidores

ABOS AGEN ALEC CGTX HURA INO MCRB SEER TIL VTGN

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

FDA expands the approved use of phentolamine ophthalmic solution 0.75% to include age-related near vision impairment, which affects millions of adults in the United States Approval supported by positive results from pivotal Phase 3 VEGA-2 and VEGA-3 trials, which met primary and all key secondary efficacy endpoints RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia in adults.

GlobeNewsWire

Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company's Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses link retinal structure to visual function, enabling focus on regions most likely to respond to treatment OPGx-LCA5 demonstrated sustained improvements in visual acuity and light sensitivity through 24 months in adults, with encouraging results in pediatric participants through six months in the Company's Phase 1/2/3 clinical trial Phase 3 clinical trial dosing for OPGx-LCA5 expected in the fourth quarter of 2026 RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), presented clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026 in Rio de Janeiro, Brazil.

GlobeNewsWire

Opus Genetics to Present at the Chardan Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the Chardan Annual Healthcare Conference on Tuesday, October 20, 2026 at 10:00 a.m.

GlobeNewsWire

Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Opus Genetics, Inc. (NASDAQ: IRD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, fifteen have given a buy recommendation and one has given

Defense World

Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD

Squarepoint Ops LLC purchased a new stake in Opus Genetics, Inc. (NASDAQ: IRD) during the quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 330,783 shares of the company's stock, valued at approximately $1,360,000. Squarepoint Ops LLC owned about 0.40% of Opus

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-21	-0.16	-0.19	-0.03
2026-05-12	-0.16	-0.75	-0.59
2025-11-12	-0.14	-0.12	0.02
2025-08-13	-0.25	-0.12	0.13
2025-05-15	-0.34	-0.32	0.02
2025-03-31	-0.34	-1.27	-0.93
2024-11-12	-0.3	-0.29	0.01
2024-08-13	-0.25	-0.3	-0.05
2024-05-10	-0.18	-0.29	-0.11
2024-03-09	-0.0525	-0.21798	-0.16548
2023-11-13	-0.222	0.2482	0.4702
2023-06-30	-0.226	-0.23669	-0.01069